BASKING RIDGE, N.J., Nov. 3, 2010 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at IMPACT 2010 held at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.  Ms. McDonald's presentation will be given at 11:13 a.m. EST on Wednesday, November 10 in the Life Science Room #106AB and will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system, REG1.  As the oldest and most established venture conference in the Northeast, IMPACT 2010 continues to offer topical speakers, relevant panel sessions, cutting-edge company presentations, unparalleled networking and visibility opportunities for both attendees and sponsors alike.

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.